Vasodilator and inotropic therapy of heart failure [panel discussion].
D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D004280:Dobutamine / Q000627:therapeutic use; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy; D009599:Nitroprusside / Q000627:therapeutic use; D010646:Phentolamine / Q000494:pharmacology / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology
D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D004280:Dobutamine; D011433:Propranolol; D011224:Prazosin; D010646:Phentolamine